{"filings":[{"id":93719,"accession_number":"0001567264-26-000047","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics Q1 net loss $2.4M; cash $10.2M; resumes trial enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.4M for Q1 2026 vs $3.3M in Q1 2025; R&D expenses fell to $1.2M from $2.2M.","Cash and equivalents $10.2M at March 31, 2026; $60M ATM facility established in March 2026.","Phase 2 INVINCIBLE-4 TNBC study: 71.4% pCR in INT230-6+SOC arm vs 33% in SOC alone; 44% fewer grade 3+ AEs.","Swissmedic approved resumption of INVINCIBLE-4 enrollment; plan to resume Q2 2026 and start France sites.","Decision to resume limited U.S. enrollment in Phase 3 INVINCIBLE-3 soft tissue sarcoma study by Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105581,"accession_number":"0001567264-26-000025","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics 2025 net loss $11.6M; cash $11.9M; TNBC trial pCR 71% vs 33%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $11.6M from $16.3M in 2024; R&D spend fell to $6.8M from $10.5M.","Cash and equivalents $11.9M at Dec 31, 2025; raised >$20M in 2025; runway into Q2 2027.","INVINCIBLE-4 TNBC trial: 5/7 (71.4%) pCR with INT230-6+SOC vs 2/6 (33%) SOC alone; fewer grade 3+ AEs.","INVINCIBLE-3 sarcoma trial paused in March 2025; 21 patients enrolled; restart depends on funding.","IT-01 study published in eBioMedicine: 75% disease control rate, median OS 11.9 months in refractory tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105580,"accession_number":"0001567264-26-000021","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intensity Therapeutics expands at-the-market offering capacity to $60 million","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on March 23, 2026 to increase ATM program from prior cap to $60.0 million aggregate.","ATM conducted through H.C. Wainwright & Co. as sales agent under agreement dated July 3, 2024.","Company has no obligation to sell any shares; issuances at its discretion based on market conditions.","Expanded facility aims to enhance financial flexibility for strategic priorities and capital access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105579,"accession_number":"0001567264-26-000014","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intensity Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed compliance with $1.00 minimum bid price after 10 consecutive business days (Feb 19–Mar 4, 2026).","Prior deficiency notice issued June 2025; extension granted until June 1, 2026; matter now closed.","Late-stage clinical biotech focused on intratumoral cancer therapies using proprietary non-covalent conjugation technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105578,"accession_number":"0001567264-26-000011","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics updates investor slide with preliminary FY2025 financial highlights","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide dated March 4, 2026, presents unaudited financial highlights through December 31, 2025.","Figures are preliminary and subject to completion of financial closing procedures; may differ materially from final results.","Slide is available on the Investor Relations section of the company's website.","No specific revenue, earnings, or balance sheet numbers are disclosed in the 8-K or its exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105577,"accession_number":"0001567264-26-000007","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Intensity Therapeutics to effect 1-for-25 reverse stock split on Feb 18 to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-25 effective 4:01 p.m. ET Feb 18, 2026; post-split trading begins Feb 19.","Pre-split shares ~63,346,579; post-split ~2,533,863; authorized shares unchanged.","Purpose is to regain compliance with Nasdaq's $1.00 minimum bid price requirement.","No fractional shares issued; cash payment in lieu at closing price on Feb 18, adjusted for split.","Stock symbol remains INTS; new CUSIP 45828J 202."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121861,"accession_number":"0001567264-25-000111","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Intensity Therapeutics receives Nasdaq extension until June 1, 2026 to meet $1 bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received 180-day extension from Nasdaq to June 1, 2026 to regain compliance with $1.00 minimum bid price rule.","Initial compliance period ended Dec 3, 2025; company previously notified of deficiency on June 6, 2025.","To regain compliance, closing bid price must be at least $1.00 for ten consecutive business days before June 1, 2026.","Company considering reverse stock split if needed; trading symbol INTS continues on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121860,"accession_number":"0001567264-25-000109","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intensity Therapeutics increases ATM offering capacity to $30M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to raise ATM program capacity to $30 million.","No obligation to issue shares; program provides financial flexibility.","ATM conducted via H.C. Wainwright & Co. LLC under existing July 2024 agreement.","Any drawdown will depend on market conditions and strategic needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121859,"accession_number":"0001567264-25-000104","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics Q3 net loss $2.7M; pauses two trials, extends cash runway to Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $2.7M for Q3 2025 vs $3.5M YoY; cash $7.1M at Sept 30, plus $6.1M raised in Q4 2025.","INVINCIBLE-4 study paused; plans protocol amendment in Q1 2026 to revise INT230-6 dosing, restart enrollment Q1 2026.","INVINCIBLE-3 study paused since March 2025 due to funding constraints; 21 patients enrolled, plan to restart with sufficient funding.","IT-01 study published in eBioMedicine: 75% disease control rate, 11.9 mo median OS; 20% abscopal effects in >40% tumor burden group.","Capital raises: $7.5M ATM in Q3, $2.1M ATM in Oct, $4.0M registered direct offering in Oct; cash runway extended to Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121858,"accession_number":"0001628280-25-047855","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Intensity Therapeutics prices $4M registered direct offering of 5M shares at $0.80","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.0M from sale of 5M shares at $0.80 per share; closing expected Nov 3, 2025.","Net proceeds to fund clinical trial advancement, working capital, and general corporate purposes.","Cash runway expected to extend to end of Q1 2027 after the offering closes.","A.G.P./Alliance Global Partners is sole placement agent; fee 7% of gross proceeds plus up to $50k expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121857,"accession_number":"0001567264-25-000096","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Intensity Therapeutics shareholders approve reverse stock split ratio of 1:5 to 1:30","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse split proposal passed with 18,333,570 For, 4,508,502 Against, 27,490 Abstain.","Adjournment proposal also approved: 18,869,741 For, 3,893,779 Against, 106,042 Abstain.","Quorum of 22,869,562 shares (46.61% of outstanding common stock) was present at the 10/22/2025 Special Meeting.","Board may set the exact ratio within 1:5 to 1:30 range or abandon the split entirely."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138548,"accession_number":"0001567264-25-000093","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Intensity Therapeutics pauses INVINCIBLE-4 enrollment after skin irritation; first Cohort A patient achieves pCR","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["First patient in Cohort A achieved pathological complete response after two INT230-6 doses plus immunochemotherapy.","Cohort A patients received INT230-6 eight days apart followed by standard-of-care immunochemotherapy.","Safety profile described as favorable, but localized skin irritation near tumor site observed in some patients.","Enrollment paused to evaluate data and implement adjustments before reopening."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138547,"accession_number":"0001567264-25-000081","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Intensity Therapeutics reduces stockholder quorum to one-third, regains Nasdaq equity compliance after $6.6M raise","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Bylaws amended to require one-third voting power for quorum (down from majority).","Company raised ~$6.6M in July 2025 via ATM to address Nasdaq equity deficiency.","Nasdaq confirmed compliance with $2.5M stockholders' equity requirement as of June 30, 2025.","Nasdaq warned that non-compliance in next periodic report could trigger delisting.","Q2 10-Q filed Aug 7, 2025, supported the equity position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138546,"accession_number":"0001567264-25-000078","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics raises $11.3M, extends cash runway to H2 2026; Q2 net loss narrows to $2.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net proceeds of ~$10.1M from two public offerings and ATM; cash runway now into H2 2026.","Q2 2025 net loss $2.5M vs $5.0M in Q2 2024; R&D expense fell to $1.5M from $3.6M.","INVINCIBLE-3 (soft tissue sarcoma) enrollment paused in March after 23 patients; existing patients continue dosing.","INVINCIBLE-4 (triple-negative breast cancer) recruiting in France and Switzerland; EMA authorized initiation.","INT230-6 showed 100% complete response in preclinical MPNST models; company believes Nasdaq compliance restored."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138545,"accession_number":"0001567264-25-000071","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intensity Therapeutics raises $6.6M via ATM stock sales; cash runway extended to H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $6.6M ($6.3M net) from sale of 19,868,658 shares at avg $0.3323/share in July 2025.","Shares outstanding post-ATM: 46,035,081 as of July 31, 2025.","Average price per share >10% higher than June 2025 public offering, reducing dilution cost.","Proceeds extend cash runway into second half of 2026 to advance clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138544,"accession_number":"0001567264-25-000069","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Intensity Therapeutics annual meeting results: director elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Mark A. Goldberg elected Class II director with 6,979,703 votes For, 222,974 Withheld.","EisnerAmper LLP ratified as independent auditor for FY2025; 10,929,292 For, 16,730 Against.","Approximately 59.73% of outstanding shares represented at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156001,"accession_number":"0001628280-25-031311","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Intensity Therapeutics raises ~$1.9M net in $0.30/share public offering for clinical studies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $2,002,500 from 6,675,000 shares at $0.30/share; underwriter exercised over-allotment for 1,001,250 additional shares.","Net proceeds ~$1.9M after underwriting discounts and expenses; offering closed June 13, 2025.","Representative's Warrants for 383,812 shares (5% of offering) issued at $0.375 exercise price, 5-year term.","Proceeds to fund INVINCIBLE-4 data readout (expected H1 2026) and continue INVINCIBLE-3 study maintenance.","ThinkEquity acted as sole book-running manager; shares traded on Nasdaq under INTS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156000,"accession_number":"0001567264-25-000056","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Intensity Therapeutics receives Nasdaq minimum bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified INTS on June 6, 2025 that bid price was below $1.00 for 30 consecutive business days.","Company has a 180-day grace period, until December 3, 2025, to regain compliance.","Compliance can be achieved if closing bid price is $1.00 or more for 10 consecutive business days.","If not compliant by deadline, INTS may seek a second grace period or consider a reverse stock split.","No immediate effect on listing or trading; stock continues on Nasdaq Capital Market under symbol INTS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155999,"accession_number":"0001567264-25-000042","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Intensity Therapeutics receives Nasdaq non-compliance notice for stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified company on May 19, 2025 of failure to meet minimum $2.5M stockholders' equity requirement.","Company has until July 3, 2025 to submit a plan to regain compliance.","If plan accepted, Nasdaq may grant up to 180-day extension from notice date.","Failure could lead to delisting of common stock (INTS); no immediate effect on listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155998,"accession_number":"0001567264-25-000040","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics pauses Phase 3 sarcoma study enrollment; Q1 net loss $3.3M, cash $0.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paused new site activations and enrollment in Phase 3 INVINCIBLE-3 sarcoma study due to funding constraints; 23 patients enrolled.","April 2025 public offering raised $2.35M gross ($1.9M net) to prioritize Phase 2 INVINCIBLE-4 breast cancer trial.","Q1 2025 net loss $3.3M (vs $4.6M Q1 2024); cash and equivalents $0.9M as of March 31, 2025.","Eight Swiss sites activated in INVINCIBLE-4; EMA authorized study in France with Unicancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155997,"accession_number":"0001628280-25-020057","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Intensity Therapeutics prices $2.35M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,133,333 shares and two series of warrants priced at $0.75 per unit; gross proceeds ~$2.35M.","Net proceeds of ~$1.9M after 7% placement agent fee and expenses.","Series B-1 warrants ($0.85 exercise, 5-yr term) and B-2 warrants ($0.85, 18-mo term).","Proceeds for INVINCIBLE-4 patient enrollment, INVINCIBLE-3 treatment, and working capital.","Offering expected to close April 28, 2025; A.G.P. and Brookline Capital Markets as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155996,"accession_number":"0001628280-25-018908","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intensity Therapeutics posts Q2 2025 corporate presentation; no new material data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation references lead candidate INT230-6 and DfuseRx platform for solid tumor treatment.","No specific clinical results, financial updates, or guidance changes are included in the filed excerpt.","Document furnished under Regulation FD; not deemed filed for SEC liability purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174459,"accession_number":"0001567264-25-000011","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics reports 2024 net loss of $16.3M; cash $2.6M; trial enrollment ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.3M for FY2024 vs $10.5M in 2023; R&D expenses rose to $10.5M from $4.8M.","Cash and cash equivalents total $2.6M as of December 31, 2024.","INVINCIBLE-3 (Phase 3 sarcoma) has 32 sites contracted, 25 patients screened; enrollment expected by first half 2026.","INVINCIBLE-4 (Phase 2 TNBC) has 8 Swiss sites activated, several patients treated; enrollment expected end Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191419,"accession_number":"0001628280-24-048910","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Intensity Therapeutics prices $3M registered direct offering and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,237,113 shares at $2.425/share for gross proceeds of ~$3M.","Issued warrants for up to 1,237,113 shares at $2.95, exercisable after 6 months, 5.5-year term.","Closing expected Nov 22, 2024; net proceeds for general working capital.","A.G.P./Alliance Global Partners lead placement agent; Brookline Capital Markets co-agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191418,"accession_number":"0001567264-24-000053","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics Q3 net loss $3.5M; first patient dosed in Phase 2 TNBC study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $3.5M for Q3 2024 vs $2.3M a year ago; R&D expenses rose to $2.2M.","Cash and equivalents $2.8M as of Sept 30, 2024; expected to fund operations into Q1 2025.","First patient dosed in Phase 2 INVINCIBLE-4 study of INT230-6 in presurgical triple-negative breast cancer.","Phase 3 INVINCIBLE-3 sarcoma study received regulatory authorizations in 8 countries; enrollment target 333 patients.","Regulatory approvals obtained from Health Canada, EMA, Swissmedic, and Australia's TGA during Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191417,"accession_number":"0001567264-24-000045","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Intensity Therapeutics grants stock options to CFO (427k shares) and controller (70k shares) at $3.44","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Options to CFO Joseph Talamo cover 427,379 shares; to Principal Accounting Officer John Wesolowski cover 70,028 shares.","Exercise price $3.44 per share, equal to fair market value on grant date (Oct 21, 2024).","Options vest in five equal annual installments beginning on the grant date.","Granted under the Company's 2021 Stock Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207902,"accession_number":"0001567264-24-000042","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics doses first patient in Phase 3 sarcoma trial; cash $6.3M into Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First patient dosed in Phase 3 INVINCIBLE-3 study of INT230-6 vs SOC in soft tissue sarcoma; plans 333 patients.","Collaboration with SAKK for Phase 2 INVINCIBLE-4 study in early-stage triple-negative breast cancer; start Q3 2024.","Net loss $5.0M in Q2 2024 vs $3.7M in Q2 2023; R&D expenses $3.6M (up from $0.9M).","Cash, cash equivalents and marketable debt securities $6.3M as of June 30, 2024.","Appointed Thomas Dubin, J.D., MPH to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207901,"accession_number":"0001567264-24-000035","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Intensity Therapeutics stockholders approve ESPP and re-elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["8,522,632 shares represented (~62.15% quorum) at July 17, 2024 annual meeting.","Daniel Donovan and Thomas I.H. Dubin re-elected as Class I directors until 2027.","Stockholders approved 2024 Employee Stock Purchase Plan (ESPP) with 6.6M for, 103k against.","EisnerAmper LLP ratified as independent auditor for fiscal year ending December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207900,"accession_number":"0001628280-24-031098","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Intensity Therapeutics enters $15M at-the-market equity offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $15M of common stock may be sold from time to time via ATM sales agent.","Sales agent commission: 3.0% of gross proceeds; agreement dated July 3, 2024.","Offering made under shelf registration statement filed same day (333-280681).","Company has no obligation to sell; may suspend or terminate the Sales Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225384,"accession_number":"0001567264-24-000021","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Intensity Therapeutics removes James Ahlers as officer; stays as consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Ahlers removed as officer effective May 21, 2024 per board resolution.","No longer designated as executive officer under Rule 16a-1(f) or Rule 3b-7.","Will continue in senior corporate finance consulting role via existing agreement with Danforth Advisors LLC.","Removal not due to any disagreement with company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225383,"accession_number":"0001567264-24-000017","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Intensity Therapeutics appoints Thomas Dubin to Board, restores Audit Committee compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas I. H. Dubin appointed as Class I director, expanding Board from 4 to 5 members.","Dubin will serve on Audit Committee, restoring Nasdaq compliance after Daniel Donovan's resignation.","Granted options to purchase 50,000 shares at $4.42 per share, vesting in four equal installments.","Dubin brings deep experience from Alexion Pharmaceuticals (former chief legal officer) and other biotech roles.","Four of five Board members are now independent per Nasdaq standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225382,"accession_number":"0001567264-24-000013","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Intensity Therapeutics enters collaboration with SAKK for Phase 2 breast cancer study of INT230-6","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SAKK to conduct Phase 2 of INVINCIBLE-4 Study testing INT230-6 plus standard of care vs standard of care alone in neoadjuvant triple negative breast cancer in Europe.","Intensity will supply INT230-6 and provide up to approximately $3.0 million in funding for the study.","Indemnification: SAKK indemnifies Intensity for claims from its study duties; Intensity indemnifies SAKK for issues from drug manufacturing, packaging, labeling.","Term runs until final clinical study report; either party may terminate for material breach, negligible scientific value, safety, or significant recruitment delay (>12 months)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225381,"accession_number":"0001567264-24-000011","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics Q1 net loss $4.6M; cash $10.5M funds operations into Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.6M in Q1 2024 vs $1.3M in Q1 2023; R&D expenses rose to $2.8M from $0.8M, G&A to $1.9M from $0.5M.","Cash, cash equivalents and marketable debt securities totaled $10.5M as of Mar 31, 2024; expected to fund operations through Q1 2025.","Intends to initiate Phase 3 INVINCIBLE-3 Study in mid-2024: INT230-6 monotherapy vs SOC in soft tissue sarcoma, 333 patients, overall survival endpoint.","Intends to initiate Phase 2/3 INVINCIBLE-4 Study in mid-2024: INT230-6 + SOC in neoadjuvant triple negative breast cancer, endpoint pCR.","Over 30 sites screened for INVINCIBLE-3; contracts in process; Phase 3 clinical supplies released and shipped."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225380,"accession_number":"0001567264-24-000003","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Intensity Therapeutics receives Nasdaq non-compliance notice after director resigns from audit committee","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Daniel Donovan resigned from audit committee on April 12, 2024, leaving only 2 members; company received Nasdaq deficiency letter on April 18, 2024.","Cure period runs until earlier of next annual stockholder meeting or April 14, 2025; if annual meeting before Oct 9, 2024, then cure expires Oct 9, 2024.","Company intends to appoint a new independent director to the board to serve on the audit committee within the cure period.","Failure to regain compliance could result in delisting; company may appeal any delisting determination to a hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244587,"accession_number":"0001628280-24-011219","cik":1567264,"company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intensity Therapeutics FY 2023 net loss $10.5M; cash $14.8M funds ops through Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.5M in 2023 vs $7.6M in 2022; includes $2.3M non-cash loss on debt conversion.","Year-end cash & investments $14.8M; company expects runway to end of Q1 2025.","R&D expenses $4.8M (vs $5.1M); G&A $3.5M (vs $2.4M) due to public-company costs.","Phase 3 sarcoma trial (INVINCIBLE-3) targeting 333 patients, overall survival endpoint; enrollment starts mid-2024.","Phase 2/3 breast cancer program (INVINCIBLE-4) to begin mid-2024; endpoint pathological complete response rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12000521.596412556,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}